CoChat

Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants

Open access

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

Therapeutic performance of recombinant antibodies relies on two independent mechanisms: antigen recognition and Fc-mediated antibody effector functions. Interaction of Fc-fragment with different FcR triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and determines longevity of the antibody in serum. In context of therapeutic antibodies FcγRs play the most important role. It has been demonstrated that the Fc-attached sugar moiety is essential for IgG effector functionality, dictates its affinity to individual FcγRs and determines binding to different receptor classes: activating or inhibitory. In this study, we systematically analyze effector functions of monoclonal IgG1 and its eight enzymatically engineered glycosylation variants. The analysis of interaction of glycovariants with FcRs was performed for single, as well as for antigen-bound antibodies and IgGs in a form of immune complex. In addition to functional properties we addressed impact of glycosylation on the structural properties of the tested glycovariants. We demonstrate a clear impact of glycosylation pattern on antibody stability and interaction with different FcγRs. Consistent with previous reports, deglycosylated antibodies failed to bind all Fcγ-receptors, with the exception of high affinity FcγRI. The FcγRII and FcγRIIIa binding activity of IgG1 was observed to depend on the galactosylation level, and hypergalactosylated antibodies demonstrated increased receptor interaction. Sialylation did not decrease the FcγR binding of the tested IgGs; in contrast, sialylation of antibodies improved binding to FcγRIIa and IIb. We demonstrate that glycosylation influences to some extent IgG1 interaction with FcRn. However, independent of glycosylation pattern the interaction of IgG1 with a soluble monomeric target surprisingly resulted in an impaired receptor binding. Here, we demonstrate, that immune complexes (IC), induced by multimeric ligand, compensated for the decreased affinity of target bound antibody towards FcRs, showing the importance of the IC-formation for the FcR- mediated effector functions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0143520

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Structures of IgG N-glycans attached to the Asn297 in the Fc domain. The core (G0) heptasaccharide is highlighted in light blue. GlcNAc, N-acetylglucosamine; Fuc, fucose; Man, mannose; Gal, galactose; NeuAc, N-acetyl neuraminic (sialic) acid.
Fig 1 Structures of IgG N-glycans attached to the Asn297 in the Fc domain. The core (G0) heptasaccharide is highlighted in light blue. GlcNAc, N-acetylglucosamine; Fuc, fucose; Man, mannose; Gal, galactose; NeuAc, N-acetyl neuraminic (sialic) acid.CC BY · PubMed Central
Fig 2 Thermal transitions of IgG1 glycovariants obtained by Thermofluor Stability Assay (TSA). Melting curves: deglycosylated (black), M3 (blue), G0 (green), G1 (pink), G2 (orange), G1+1SA (light blue), G2+1SA (yellow), G2+2SA (purple), WT (red).
Fig 2 Thermal transitions of IgG1 glycovariants obtained by Thermofluor Stability Assay (TSA). Melting curves: deglycosylated (black), M3 (blue), G0 (green), G1 (pink), G2 (orange), G1+1SA (light blue), G2+1SA (yellow), G2+2SA (purple), WT (red).CC BY · PubMed Central
Fig 3 SPR analysis of interaction of IgG1 glycovariants with FcγRs. Anti His-antibody immobilized on the chip, glycovariants were injected as analytes, after capturing of the respective receptors: A. FcγRI, B. FcγRIIa, C. FcγRIIb and D. FcγRIIIa. Binding of WT antibody was set as 100%. Each graph represents results from at least three independent experiments; data are given as means ± SD.
Fig 3 SPR analysis of interaction of IgG1 glycovariants with FcγRs. Anti His-antibody immobilized on the chip, glycovariants were injected as analytes, after capturing of the respective receptors: A. FcγRI, B. FcγRIIa, C. FcγRIIb and D. FcγRIIIa. Binding of WT antibody was set as 100%. Each graph represents results from at least three independent experiments; data are given as means ± SD.CC BY · PubMed Central
Fig 4 SPR analysis of the interaction of target-bound or F(ab’)2 <Fab-captured IgG1 glycovariants with FcγRs. Glycovariants were injected to bind antigen (A) or F(ab’)2 <Fab> (B), immobilized on the chip, followed by the application of the respective receptors: FcγRI (black), FcγRIIa (grey), FcγRIIb (dark grey) and FcγRIIIa (light grey). Binding of WT antibody was set as 100% Each graph represents results from at least three independent experiments; data are given as means ± SD.
Fig 4 SPR analysis of the interaction of target-bound or F(ab’)2 <Fab-captured IgG1 glycovariants with FcγRs. Glycovariants were injected to bind antigen (A) or F(ab’)2 <Fab> (B), immobilized on the chip, followed by the application of the respective receptors: FcγRI (black), FcγRIIa (grey), FcγRIIb (dark grey) and FcγRIIIa (light grey). Binding of WT antibody was set as 100% Each graph represents results from at least three independent experiments; data are given as means ± SD.CC BY · PubMed Central
Fig 5 Retention profiles of the IgG1 glycovariants obtained by analytical FcγRIIIa affinity chromatography. The chromatograms, obtained by monitoring signal at 280 nm, show two peaks corresponding to fucosylated and afucosylated antibody fractions (deglycosylated IgG is not shown).
Fig 5 Retention profiles of the IgG1 glycovariants obtained by analytical FcγRIIIa affinity chromatography. The chromatograms, obtained by monitoring signal at 280 nm, show two peaks corresponding to fucosylated and afucosylated antibody fractions (deglycosylated IgG is not shown).CC BY · PubMed Central
Fig 6 Binding of glycovariants to FcγRIIIa, expressed on living cells. Unlabeled glycovariants compete for binding to receptor with acceptor-labeled antibody, resulting in decrease of FRET signal: deglycosylated (red diamonds), WT (black circles), G0 (black triangles), G1(black inverted triangles), G2 (black squares). Initial signal was normalized to 1. (For remaining glycovariants refer to S3 Fig).
Fig 6 Binding of glycovariants to FcγRIIIa, expressed on living cells. Unlabeled glycovariants compete for binding to receptor with acceptor-labeled antibody, resulting in decrease of FRET signal: deglycosylated (red diamonds), WT (black circles), G0 (black triangles), G1(black inverted triangles), G2 (black squares). Initial signal was normalized to 1. (For remaining glycovariants refer to S3 Fig).CC BY · PubMed Central
Fig 7 Interaction of target- or F(ab’)2 <Fab>-bound IgG with FcγRIIIa. Prior to interaction analysis IgG was incubated with its monomeric target (A, B) or with F(ab’)2 <Fab> (C, D) and loaded onto affinity column (A, C) and examined by SPR (B, D). The IgG: ligand ratio: 1:0 (red), 1:1 (green), 1:2 (blue) and 1:4 (pink).
Fig 7 Interaction of target- or F(ab’)2 <Fab>-bound IgG with FcγRIIIa. Prior to interaction analysis IgG was incubated with its monomeric target (A, B) or with F(ab’)2 <Fab> (C, D) and loaded onto affinity column (A, C) and examined by SPR (B, D). The IgG: ligand ratio: 1:0 (red), 1:1 (green), 1:2 (blue) and 1:4 (pink).CC BY · PubMed Central
Fig 8 Interaction of IgG1 glycovariants with FcRn. Comparison of different SPR experimental set-ups: FcRn receptor was captured by Anti-6xHis antibody, followed by the application of IgG glycovariants (black); FcRn was directly immobilized onto the chip surface, subsequently IgG glycovariants were loaded (grey); glycovariants were captured by the immobilized protein L, followed by the application of FcRn (dark grey); glycovariants were bound onto the immobilized target, then the receptor was applied (light grey).
Fig 8 Interaction of IgG1 glycovariants with FcRn. Comparison of different SPR experimental set-ups: FcRn receptor was captured by Anti-6xHis antibody, followed by the application of IgG glycovariants (black); FcRn was directly immobilized onto the chip surface, subsequently IgG glycovariants were loaded (grey); glycovariants were captured by the immobilized protein L, followed by the application of FcRn (dark grey); glycovariants were bound onto the immobilized target, then the receptor was applied (light grey).CC BY · PubMed Central
Fig 9 Retention profiles of IgG1 glycovariants obtained by analytical FcRn affinity chromatography.
Fig 9 Retention profiles of IgG1 glycovariants obtained by analytical FcRn affinity chromatography.CC BY · PubMed Central
Fig 10 Interaction of target bound IgG with FcRn obtained by affinity chromatography and SPR. A. Retention profiles of IgG incubated in different ratios with its monomeric target. C. Retention profiles of IgG incubated in different ratios with F(ab’)2 <Fab>. B and D SPR analysis of interaction of IgG incubated with monomeric target and F(ab’)2 <Fab> respectively. Antibody: ligand ratio: 1:1 (green), 1:2 (blue), 1:4 (pink), IgG alone (red).
Fig 10 Interaction of target bound IgG with FcRn obtained by affinity chromatography and SPR. A. Retention profiles of IgG incubated in different ratios with its monomeric target. C. Retention profiles of IgG incubated in different ratios with F(ab’)2 <Fab>. B and D SPR analysis of interaction of IgG incubated with monomeric target and F(ab’)2 <Fab> respectively. Antibody: ligand ratio: 1:1 (green), 1:2 (blue), 1:4 (pink), IgG alone (red).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 27

  1. R Kapur, 2014, IgG-effector functions: "The Good, The Bad and The Ugly", Immunol Lett
  2. RM Anthony, 2012, Novel roles for the IgG Fc glycan, Ann N Y Acad Sci, 1253, 170, 10.1111/j.1749-6632.2011.06305.x · DOI · Paper page
  3. PM Hogarth, 2012, Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond, Nat Rev Drug Discov, 11, 311, 10.1038/nrd2909 · DOI · Paper page
  4. XR Jiang, 2011, Advances in the assessment and control of the effector functions of therapeutic antibodies, Nat Rev Drug Discov, 10, 101, 10.1038/nrd3365 · DOI · Paper page
  5. R Jefferis, 2009, Glycosylation as a strategy to improve antibody-based therapeutics, Nat Rev Drug Discov, 8, 226, 10.1038/nrd2804 · DOI · Paper page
  6. Y Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594 · DOI · Paper page
  7. W Huang, 2012, Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions, J Am Chem Soc, 134, 12308, 10.1021/ja3051266 · DOI · Paper page
  8. TS Raju, 2008, Terminal sugars of Fc glycans influence antibody effector functions of IgGs, Curr Opin Immunol, 20, 471, 10.1016/j.coi.2008.06.007 · DOI · Paper page
  9. Y Mimura, 2000, The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms, Mol Immunol, 37, 697, 10.1016/S0161-5890(00)00105-X · DOI · Paper page
  10. PM Buck, 2013, Consequences of glycan truncation on Fc structural integrity, MAbs, 5, 904, 10.4161/mabs.26453 · DOI
  11. V Kayser, 2011, Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies, Biotechnol J, 6, 38, 10.1002/biot.201000091 · DOI · Paper page
  12. S Bohm, 2012, The role of sialic acid as a modulator of the anti-inflammatory activity of IgG, Semin Immunopathol, 34, 443, 10.1007/s00281-012-0308-x · DOI
  13. Y Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594 · DOI · Paper page
  14. RM Anthony, 2012, Novel roles for the IgG Fc glycan, Ann N Y Acad Sci, 1253, 170, 10.1111/j.1749-6632.2011.06305.x · DOI · Paper page
  15. R Jefferis, 1993, The glycosylation of antibody molecules: functional significance, Glycoconj J, 10, 358
  16. R Jefferis, 2012, Isotype and glycoform selection for antibody therapeutics, Arch Biochem Biophys, 526, 159, 10.1016/j.abb.2012.03.021 · DOI · Paper page
  17. PM Buck, 2013, Consequences of glycan truncation on Fc structural integrity, MAbs, 5, 904, 10.4161/mabs.26453 · DOI
  18. R Jefferis, 2012, Isotype and glycoform selection for antibody therapeutics, Arch Biochem Biophys, 526, 159, 10.1016/j.abb.2012.03.021 · DOI · Paper page
  19. V Kayser, 2011, Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies, Biotechnol J, 6, 38, 10.1002/biot.201000091 · DOI · Paper page
  20. Y Mimura, 2000, The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms, Mol Immunol, 37, 697, 10.1016/S0161-5890(00)00105-X · DOI · Paper page
  21. TS Raju, 2008, Terminal sugars of Fc glycans influence antibody effector functions of IgGs, Curr Opin Immunol, 20, 471, 10.1016/j.coi.2008.06.007 · DOI · Paper page
  22. K Zheng, 2011, The impact of glycosylation on monoclonal antibody conformation and stability, MAbs, 3, 568, 10.4161/mabs.3.6.17922 · DOI · Paper page
  23. D Houde, 2010, Post-translational modifications differentially affect IgG1 conformation and receptor binding, Mol Cell Proteomics, 9, 1716, 10.1074/mcp.M900540-MCP200 · DOI · Paper page
  24. Y Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594 · DOI · Paper page
  25. A Lux, 2013, Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs, J Immunol, 190, 4315, 10.4049/jimmunol.1200501 · DOI · Paper page
  26. DC Roopenian, 2007, FcRn: the neonatal Fc receptor comes of age, Nat Rev Immunol, 7, 715, 10.1038/nri2155 · DOI · Paper page
  27. MK Leabman, 2013, Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys, MAbs, 5, 896, 10.4161/mabs.26436 · DOI · Paper page

Cited by

See all 101

Metadata

Authors
Dashivets, T., Thomann, M., Rueger, P., Knaupp, A., Buchner, J., & Schlothauer, T.
Affiliations
  • Center for Integrated Protein Science Munich (DE)
  • Roche Pharma AG (Germany) (DE)
Corresponding author
Schlothauer, Tilman
Venue
PLOS ONE
Published
2015-12-11
Volume
10
Issue
12
Pages
e0143520
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2190603070
Cited by
101
References
69
Citations by year
2026: 2 · 2025: 7 · 2024: 8 · 2023: 12 · 2022: 7 · 2021: 13 · 2020: 12 · 2019: 10 · 2018: 8 · 2017: 14 · 2016: 7 · 2015: 1
FWCI
8.09
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
Roche Innovation Center Zurich
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Keywords
IgG glycosylation, Fc gamma receptor, antibody effector functions, therapeutic monoclonal antibodies, FcγRI, FcγRIIa, FcγRIIB, FcγRIIIa, neonatal Fc receptor, galactosylation, sialylation, deglycosylation, immune complexes, antibody stability, antibody structure, antibody-drug conjugates
MeSH terms
Antibodies, Monoclonal, Antibody Affinity, Antigen-Antibody Complex, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Galactose, Glycosylation, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Molecular Sequence Data, Protein Binding, Recombinant Proteins, Sialic Acids, Protein Engineering, Gene Expression, Receptors, IgG, Surface Plasmon Resonance, Protein Stability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.